OpenAI acquires Orchestra Bio
OpenAI will merge Orchestra Bio's team and coordination platform into its Rosalind life sciences AI suite.
- Orchestra Bio provides AI agents that monitor biopharma studies, manage project dependencies, and assess trial timeline risks
- The acquired technology will integrate with GPT-Rosalind and Rosalind Workbench to connect research reasoning with operational planning
Biopharma teams using OpenAI's life sciences tools gain agentic workflow features to coordinate experiments, manufacturing, and clinical trial schedules.
